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Abstract
Tumor metabolism is a thrilling discipline that focuses on mechanisms used by cancer cells to earn crucial building
blocks and energy to preserve growth and overcome resistance to various treatment modalities. At the same time,
therapies directed specifically against aberrant signalling pathways driven by protein tyrosine kinases (TKs) involved
in proliferation, metastasis and growth count for several years to promising anti-cancer approaches. In this respect,
small molecule inhibitors are the most widely used clinically relevant means for targeted therapy, with a rising number
of approvals for TKs inhibitors. In this review, we discuss recent observations related to TKs-associated metabolism and
to metabolic feedback that is initialized as cellular response to particular TK-targeted therapies. These observations
provide collective evidence that therapeutic responses are primarily linked to such pathways as regulation of lipid and
amino acid metabolism, TCA cycle and glycolysis, advocating therefore the development of further effective targeted
therapies against a broader spectrum of TKs to treat patients whose tumors display deregulated signalling driven by
these proteins.
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Background
The switch from normal tissue to malignancy is a result
of oncogenes-driven biochemical processes aimed at sus-
taining an accelerated rate of proliferation and growth
[1]. Otto Warburg in 1956 described for the first time a
specific metabolic characteristic of neoplasms by demon-
strating that a cancer cell, unlike an untransformed cell,
relies mainly on a higher glycolytic flux without a change
in oxidative phosphorylation even in the presence of
oxygen [2]. The so-called Warburg effect is nowadays
considered a major hallmark of cancer and numerous
studies have been repeatedly reporting that various
metabolic pathways appear to be distinctive in individual
tumour cells [3, 4]. Many of these alterations emerge as
a consequence of the gain of mutations accumulated
during oncogenesis, providing proliferative advantage for
cancer cells in their microenvironment.
In recent years, in addition to investigating the role of
cell metabolism in tumor cell development, particular
attention has been devoted to metabolic changes occur-
ring as a response to targeted treatments [5–7]. In view
of the role that TKs seem to play in the regulation of
cellular metabolism [8–11], it is crucial to determine
whether the antitumor activity of particular tyrosine kin-
ase inhibitors (TKIs) is related to their effect at a given
metabolic level. Such insights may subsequently serve as
an important ground for novel personalized therapeutic
options and combination treatments. Assessment of bio-
logical conformity in changes in metabolites following
administration of a particular TKI has already shown to
provide important translational observations as to par-
ticular sensitive metabolic pathways [12]. Consequently,
metabolomics has the potential to identify subgroups of
patients that are likely to profit from given targeted per-
turbations and, of a similar importance, determine sub-
groups that may encounter toxicity or resistance.
Protein kinases constitute an immense enzyme family
that emerges as a strikingly valuable set of targets in
therapy of various tumors considering their high sensi-
tivity to specific kinase inhibitors, which are often rela-
tively well tolerated by normal cells. Development of
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TKIs created a therapeutic window for selective dimin-
ishing of malignancies with constitutively active kinase.
The majority of these compounds share a common
mechanism of action – they competitively inhibit adeno-
sine triphosphate (ATP) at the catalytic binding site of
the targeted protein [13]. As aforementioned, accumulat-
ing evidence suggests that key oncogenic pathways pro-
gram the adaptation of metabolism with explicit changes
for the selective advantage of tumor cells, many of them
regulated by tyrosine kinase activity [14–16]. In this re-
view, we summarize and discuss principal metabolic
changes following administration of particular kinase in-
hibitors on different levels of cellular metabolism (key
metabolites and molecules affected by TKIs in cancer
are summarized in Table 1).
Impact of TKIs on Glycolysis and glucose-related
pathways
As metabolic reprogramming towards aerobic glycolysis
has been suggested as one of the hallmarks of cancer,
considerable research efforts focused for over a decade
on enzymes and metabolites of the glycolytic pathway
following antineoplastic treatments. Glucose metabol-
ism, a paramount energetic resource for the cell, is a
very complex process regulated in neoplastic cells by dif-
ferent oncogenes on multiple levels, ranging from tran-
scription to post-translation modifications [14]. In that
respect, for example, c-MYC controls key metabolic
enzymes including those that are involved in glucose
metabolism such as hexokinase 2 (HK2), glucose trans-
porter 1 (GLUT1), pyruvate kinase muscle isozyme 2
(PKM2) and lactate dehydrogenase A (LDHA) [17].
Oncogene-conducted activation of glycolytic pathway
takes frequently place through hypoxia-inducible factor
1α (HIF-1α) [18, 19]. The already mentioned Warburg
effect is a result of deregulated genes, leading to upre-
gulation of glucose transporters 1 and 3, with resulting
elevated glucose consumption [20, 21]. Glucose metabol-
ism does not necessarily encompass glycolysis only. In-
deed, other glucose-related metabolic pathways, as the
pentose phosphate pathway (PPP), which provides ni-
cotinamide adenine dinucleotide phosphate (NADPH),
the hexosamine pathway, a minor branch of glycolysis
needed for glycosylation of proteins, and glycogenesis
that generates glycogen used as a glucose repository, are
all critical branches of cellular glucose metabolism [22].
Since it has been shown that many RTKs inhibitors sup-
press among others also metabolic pathways as for ex-
ample the PI3K/Akt pathway, it is expected that they
would inhibit glucose metabolism in a similar manner
[23, 24]. In this section we summarize how glycolysis
and other glucose-related pathways are reprogrammed
in malignant cells following particular TKI targeting
(summarized in Fig. 1).
ErbB family
Epidermal growth factor receptor (EGFR)
EGFR, a broadly studied RTK system, is overexpressed,
deregulated and mutated in a large number of malignan-
cies. Specifically, EGFR protein overexpression was de-
tected in tumors of breast, brain, cervix, ovary, colon,
head and neck and lung [25, 26], creating a strong motiv-
ation to develop novel antitumor agents focused on EGFR.
The 2014 study from Makinoshima and collaborators
[27] provided one of the first comprehensive analyses of
EGFR TKI-mediated modulations of metabolism. The
presence of EGFR TKIs erlotinib (Tarceva®) and gefitinib
(Iressa®) repressed lactate production and glucose con-
sumption in three distinct lung adenocarcinoma
(LAD) cell lines, HCC827, NCI-H1975 and PC-9 [27].
Importantly, HCC827 and PC-9 both carry the EGFR
exon 19 delE746-A750 mutation and are sensitive to
EGFR TKIs whereas H1975 harbors the EGFR L858R +
T790 M mutation, which causes resistance to both gefi-
tinib and erlotinib [28]. The authors hypothesized that
lactate production is regulated by MYC via transcrip-
tional regulation, since MYC is decreased at both protein
and mRNA levels following treatment by EGFR TKIs.
Interestingly, western blot analysis showed that MYC-
regulated proteins HK2 and GLUT3, but not GLUT1,
were reduced in EGFR TKI-sensitive cell lines upon
treatment [27]. Metabolome analysis using Capillary
Electrophoresis Time of Flight Mass Spectrometer (CE-
TOFMS) exposed intermediate key metabolites in glucose
metabolism that were altered following erlotinib treatment
in both EGFR TKI-sensitive cell lines HCC827 and PC-9.
Specifically, fructose 1,6-bisphosphate (FBP), dihydro-
xyacetone phosphate (DHAP), 3-phosphoglycerate
(3PG), phosphoenolpyruvate (PEP), lactate (LA), and 6-
phosphogluconate (6PG) were all decreased in TKI-
sensitive HCC827 and PC9 cells after 6 h of erlotinib
treatment, but not in TKI-resistant NCI-H1975 cells
[27]. Furthermore, PPP metabolites, glucose 6-
phosphate (G6P), glyceraldehyde 3-phosphate (G3P),
pyruvate (PA), ribulose 5-phosphate (Ribu5P), and ri-
bose 5-phosphate (R5P) were significantly reduced in
both HCC827 and PC9 cells [27]. Measuring the extra-
cellular acidification rate (ECAR), an indirect readout
of the glycolytic rate, Lim et al. reported an attenuation
of ECAR by the co-treatment with EGF stimulation to-
gether with gefitinib in an EGFR-overexpressing breast
cancer cell line MDA-MB-468 [29]. Moreover, they
showed that EGFR binds, phosphorylates and inhibits
PKM2, a rate-limiting glycolytic enzyme that catalyses
the last glycolysis step [29]. On the contrary, ECAR was
increased in triple-negative breast cancer (TNBC)
mesenchymal-like cell lines MDA-MB-231 and Hs578T
upon treatment by erlotinib or the MET inhibitor cap-
matinib (INC280) [30]. The impact of EGFRi on
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glycolysis was further confirmed by the Heath group in
2015, who reported, as assessed by the 18F–FDG radioas-
say, a reduction of consumption of glucose and hexokinase
activity following erlotinib treatment in patient-derived
glioblastoma (GBM) neurosphere tumor cells (GBM39)
that express EGFR [31]. Outlining similarities with other
authors’ models, further recent report conducted by De
Rosa et al., where one EGFR inhibition-sensitive cell line
(HCC827) and two EGFR inhibition-resistant cell lines
(H1975 and H1993 (both bearing MET gene amplifi-
cation)) were exposed to WZ4002 (a specific EGFRT790M
inhibitor), erlotinib or PHA665752 (a first generation
Table 1 Summary of key metabolites and molecules affected by TKIs in cancer. Up- or downregulation highly depends on the
inhibitor and model of the study used
Metabolite Function in Sense of Regulation Rerence(s)
Fructose 1,6-bisphosphate glycolysis ↓ [27, 34, 38, 41, 45, 48, 49, 58]
Dihydroxyacetone phosphate
3-phosphoglycerate
Glucose (consumption)
Phosphoenolpyruvate glycolysis and gluconeogenesis ↓ [22, 27, 38, 45]
Lactate
Glyceraldehyde 3-phosphate
Pyruvate
6-phosphogluconate pentose phosphate pathway ↓ [27, 58]
Ribulose-5-phosphate
Ribose-5-phosphate
Xylulose-5-phosphate
D-sedoheptulose 1,7-bisphosphate pentose phosphate pathway ↑ [34]
Deoxyribose phosphate
Glucose-6-phosphate glycolysis and PPP ↓ [27, 58]
Glutamate amino acid metabolism ↑ [27, 30, 34, 45, 74]
Valine
Lysine
Tyrosine
Aspartate
Proline
Threonine
Histidine
Asparagine
Tryptophan
Alanine
NADPH pentose poshosphate pathway ↓ [34, 51]
oxidation-reduction pathways
ATP, GTP, CTP, TTP energy metabolism ↑ [32, 45, 58]
Fumarate TCA cycle ↓ [27, 30]
Malate
Citrate
Arginine amino acid metabolism ↓ [74, 76]
Citrate TCA cycle ↑ [32]
ATP energy metabolism ↓ [60, 62]
Phosphocholine glycerophospholipid metabolism ↓ [45, 87–89]
Abbreviations: ↑—Up-regulation; ↓—Down-regulation; TCA cycle Tricarboxylic acid cycle; NADPH Nicotinamide adenine dinucleotide phosphate; ATP Adenosine
triphosphate; GTP Guanosine triphosphate; CTP Cytidine triphosphate; TTP Thymidine triphosphate
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MET inhibitor) and their impacts on glycolytic enzymes
and transporters were investigated [32]. Although protein
levels of HKI, PKM1/2 and GLUT1 remained consistent
across all cell lines, all three studied inhibitors led to a
concentration-dependent downregulation of HKII and to
upregulation of levels of GLUT3 with efficient inhibitors
of the corresponding cell line (curiously, the levels of
GLUT3 were upregulated after 72 h treatment of H1975
with WZ4002 or following treatment of H1993 cells with
PHA665752) [32]. Moreover, a reduction of pPKM2 was
observed in HCC827 and H1993 treated with erlotinib
and PHA665752, respectively [32]. The in vitro observa-
tions were further substantiated in vivo by using H1975
and H1993 cells injected into female BALB/c (nu/nu) mice
treated with WZ4002 and crizotinib (Xalkori® a MET in-
hibitor), respectively [32]. This differential regulation of
glycolysis brings a rationale for a potential combination
therapy targeting both the EGFR pathway and glucose
Fig. 1 TKI-induced regulation of glycolytic pathway. Highlighted in bold are proteins and metabolites (blue) together with glycolytic regulators
(red) that were shown to be affected by the inhibition of TKs. Abbreviations: GLUT1/3—glucose transporter 1/3; HK1/2/3—hexokinase 1/2/3;
TIGAR—TP53-inducible glycolysis and apoptosis regulator; P—phosphate; BP—bisphosphate; PPP—pentose phosphate pathway; GPI—glucose-6-
phosphate isomerase; PFKFB2— 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2; PFK—6- phosphofructokinase(three isoforms – muscle
(PFKM), liver (PFKL) and platelet (PFKP)); FBP1/2—fructose-bisphosphatase 1/2; ALDOA/B/C—aldolase A/B/C; TPI1—triosephosphate isomerase;
PGAM1/2—phosphoglycerate mutase 1/2; ENO1/2/3—enolase 1/2/3; PKM2—pyruvate kinase isozyme M2; PKLR—Pyruvate kinase isozymes L/R;
LDHA/B/C—lactate dehydrogenase A/B/C; TCA cycle—tricarboxylic acid cycle
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metabolism for enhanced therapeutic effect [32]. Interest-
ingly, the impact of EGFR inhibition on glucose-related
metabolism was recently substantiated both in cell culture
and in vivo using HCC827 and H1650 (bearing E746-
A750 deletion of exon 19) cell lines, where erlotinib ther-
apy reduced expression of MYC and HIF1α and their
downstream targets GLUT1, HKII, neutral amino acid
transporter B(0) (SLC1A5) together with sodium-coupled
neutral amino acid transporter 1 (SLC38A1) [33]. These
results further correlated with decreased 18F–FDG and
11C–Gln uptake seen in HCC827 xenografts following the
erlotinib treatment [33]. In addition, metabolic profiling of
myeloma cancer cells LP-1 (no NRAS, KRAS or BRAF
mutation), L-363 (harbouring NRAS mutation), RPMI-
8226 (KRAS mutation), and U-266 (BRAF mutation) re-
vealed that following the treatment with gefitinib, metabo-
lites from the PPP such as ribose-phosphate, D-
sedoheptulose-1,7-bisphosphate, O8P-O19 and deoxyri-
bose phosphate were significantly increased in LP-1 cell
line and unchanged in KRAS/NRAS/BRAF mutant
myeloma cancer cells [34]. As PPP is a main source of
NADPH supplying R5P for nucleotide synthesis, the au-
thors hypothesized that the upregulation of these me-
tabolites is a metabolic compensatory mechanism to
prevent complete therapeutic response towards EGFR
inhibition [34]. This hypothesis was experimentally
confirmed by the use of the antimetabolite 6AN, a PPP
inhibitor, together with gefitinib [34] The combin-
ational therapy supressed the proliferation of LP-1 cells,
which was recovered by supplementation of NADPH.
Analogous results were reported using afatinib (Gio-
trif®), a dual EGFR and ERBB2 inhibitor [34] as well as
in another study, where MET or EGFR inhibition both
sensitized TNBC cell line MDA-MB-468 to nucleotide
enzymes knockdown [30].
HER2
Similarly to EGFR, HER2, encoded by the ERBB2 gene,
is also often overexpressed in cancer and its deregulation
is associated with aggressive phenotype and shortened
survival [35]. Targeting HER2 by the humanized murine
monoclonal antibody trastuzumab (Herceptin®) leads to
a 40% improved overall survival in patients with breast
cancer that show approximately 15%–25% amplification
or overexpression of HER2 [36, 37].
Zhao et al. reported that trastuzumab inhibits glucose
uptake and lactate production in BT474 and ZR-7530
breast cancer cell lines without a change in cell growth
inhibition, hypothesising that glycolysis inhibition is not
a consequence of the cell growth inhibition [38]. Their
previous study showed that the ErbB2-heat shock fac-
tor1 (HSF1)-lactate dehydrogenase A (LDHA) pathway
has a main role in glucose regulation in breast cancer
cells [39]. Therefore they suggested and subsequently
also reported that trastuzumab inhibits glycolysis
through downregulation of the HSF1-LDHA axis and,
moreover, this axis contributes to the resistance of
breast cancer cells to this monoclonal antibody [38].
Similar response on glycolysis was shown with lapatinib
(Tykerb®), a dual inhibitor of EGFR and ErbB2/HER2
that is usually used in combination with capecitabine for
the treatment of HER2-positive metastatic breast cancer
[40]. Specifically, Komurov et al. reported that lapatinib
treatment of ErbB2-positive SKBR3 breast cancer cells
induced glucose deprivation, suggesting a blockage of
glucose-dependent EGFR/HER2 signaling [41]. Add-
itional study by Ruprecht et al. unveiled that phosphor-
ylation of Ser466 of 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase 2 (PFKFB2) is inhibited following
lapatinib treatment in lapatinib-sensitive BT-474 breast
cancer cell line, however it recovers to its initial levels of
phosphorylation in lapatinib-resistant BT-474 clone BT-
474-J4 [42]. Phosphorylation of Ser466 was reported to
trigger PFKFB2 kinase activity that activates the produc-
tion of metabolite fructose-2,6-bisphosphate, pointing
out a possible link between lapatinib therapeutic action
and metabolic reprogramming in resistance [42].
The results of research efforts focusing on ErbB2 fam-
ily of RTKs strongly suggest that the decrease of inter-
mediate metabolites in PPP and glycolysis such as
lactate, FBP, G6P or R5P and the impairment of
glycolysis-related enzymes such as GLUT1 and HK1 are
not events resulting from inhibited proliferation but
could potentially serve as biomarkers to predict the re-
sponse to and, more importantly, efficacy of EGFR and
HER2 TKI treatment.
BCR-ABL
BCR-ABL harbours a constitutively active form of the
ABL TK and is present in more than 90% of chronic
myeloid leukemia (CML) patients [43]. CML treatment
was revolutionized by the use of the BCR-ABL TKI ima-
tinib (formerly STI571, Gleevec®), a compound that was
writing the first success stories in the field of targeted
neoplastic treatment [43]. Imatinib provides effective
and durable therapy: the treatment resulted in 5-year
survival of approximately 90% for CML patients in clin-
ical trials [44].
In 2004, Gottschalk et al. reported that imatinib treat-
ment changed glucose metabolism from anaerobic gly-
colysis to the aerobic mitochondrial TCA cycle in two
human BCR-ABL-positive cell lines CML-T1 and K562
but not in BCR-ABL-negative cell line HC-1 [45]. Interest-
ingly, metabolic responses to imatinib were dependent on
the concentration of the molecule. When using a concen-
tration of 0.25 μmol/L, which is below imatinib’s IC50
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value (for CML-T1 IC50 is 0.69 ± 0.06 μmol/L and for
K562 IC50 is 0.47 ± 0.04 μmol/L), lactate production was
reduced in BCR-ABL-positive cell lines and concurrently,
the production of glutamate increased, thus suggesting in-
creased employment of the mitochondrial glucose path-
way; when using a concentration above its IC50 value
(2.5 μmol/L), no activation of TCA cycle was observed
[45]. Moreover, imatinib was able to increase extracellular
glucose in the lyophilized media of BCR-ABL-positive cell
lines in contrary to media coming from the BCR-ABL-
negative cell line, where the concentration of extracellular
glucose did not change [45]. Consequently, this resulted
in an increased ratio of extracellular to intracelullar glu-
cose and decreased glucose uptake in BCR-ABL-positive
cells [45]. These data correlate with previous findings of
Boros et al. who showed that imatinib regulates glycolysis
through downregulation of GLUT1 in human leukemia
cells [46]. In fact, BCR-ABL-positive haemopoietic cells
TonB210 express high affinity GLUT1 and demonstrate
increased glucose uptake [47]. Following the treatment in
vitro, imatinib led to the internalization of 90% of GLUT1
and drastically decreased hexose uptake [47]. A study car-
ried out by the group of Serkova et al. aimed at under-
standing of development of imatinib resistance metabolic
phenotype in CML, using imatinib-sensitive K562-s and
LAMA84-s and imatinib-resistant K562-r and LAMA84-r
cell lines [48]. By using nuclear magnetic resonance spec-
troscopy and gas chromatography mass spectrometry to
assess 13C glucose uptake and metabolism, they showed
that in both imatinib-sensitive cell lines, imatinib treat-
ment (1 μmol/L) significantly decreased glucose uptake
and lactate export together with reduced [4-13C]glu-
tamate, in contrast to imatinib-resistant cell lines, sug-
gesting a decrease in the activity of glycolysis together
with TCA cycle [48]. To confirm their findings, they used
2-deoxy-d-glucose uptake assay and showed that
imatinib-sensitive cell lines displayed decreased uptake of
glucose, compared to imatinib-resistant cell lines that ex-
hibit even higher glucose uptake, as a possible conse-
quence of imatinib resistance progress [48]. To explain
the drop in glucose uptake in imatinib-sensitive cell lines,
they reported that imatinib inhibits glycolysis and translo-
cates GLUT1 from the membrane into the cytosol,
whereas GLUT1 remains located at the plasma membrane
in resistant cell lines [48]. Interestingly, a decrease in 18-
fluoro-2-deoxy-D-glucose (FDG) uptake was previously
described in a case report of a patient with a jejunal
gastrointestinal stromal tumor with multiple hepatic me-
tastases treated with imatinib [49].
Studies employing BCR-ABL targeted therapy provided
a rationale for the combined use of an inhibitor of glucose
metabolism and kinase inhibitors for treatment of BCR-
ABL-positive patients who acquired resistance either to
classical chemotherapy or to the targeted treatment.
Met
The MET RTK for hepatocyte growth factor (HGF) is,
analogously to other RTKs, actively involved in cell
growth, migration and proliferation and additionally
functions also as a main regulator of embryogenesis
[50]. In a study published in 2011, Lui et al. used two
nasopharyngeal cancer (NPC) cell lines, HK1-LMP1 and
CNE-2, and described that protein levels of regulator of
apoptosis and glycolysis, TP53-induced Glycolysis and
Apoptosis Regulator (TIGAR), were reduced after the
treatment with two MET TKIs (by AM7, a MET inhibi-
tor binding to the kinase linker region and extending to
a hydrophobic binding site and by a tool compound
SU11274), indicating that the effect is induced by METi
itself and does not depend on the exact nature of inhibi-
tor used [51]. Previously, it was proposed that TIGAR
inhibits apoptosis by regulation of cellular NADPH
levels and via regulation of the PPP [52]. Indeed, they
explored METi reduction of intracellular NADPH, a
protector from oxidative stress and a driver of the force
of most biosynthetic enzymatic reactions, responsible for
biosynthesis of DNA, RNA, cholesterol and fatty acids
[53, 54], in both NPC cell lines [51]. Interestingly, using
a METi-sensitive SNU5 and METi-resistant SNU1 gastric
cancer cell lines, expression of several glycolysis-related
mitochondrial enzymes, such as voltage-dependent anion-
selective channel protein 1 (VDAC1) and adenine nucleo-
tide translocase 2 (ANT2), was significantly regulated in
response to MET inhibitor PHA665752 [55]. Impact of
MET inhibition on glucose metabolism was confirmed
using H1975 NSCLC cancer cells in a xenograft model
(Ncr-nu mice) monitored in vivo by FDG-PET (glucose
analogue [18F]fluoro-2-deoxy-D-glucose-positron emis-
sion tomography) analysis with MRI [56]. Indeed, MET
inhibitor SU11274-treated xenografts displayed a 45%
drop in glucose metabolism compared to untreated
controls [56].
In conclusion, analogously to findings pertaining to in-
hibition of ErbB2 family of receptors, MET inhibition
also seems to modulate glucose metabolism and this ob-
servation could potentially serve as a mean to predict can-
cer cells responses to MET targeting-based treatments.
Other protein TKs
Anaplastic lymphoma kinase (ALK) is engaged in the in-
duction and progression of various cancer types, including
non-small cell lung cancer (NSCLC), neuroblastomas and
lymphomas. ALK is usually targeted in clinical practice by
crizotinib, approved for use in ALK-positive NSCLC [57].
Some preliminary work on impacts of ALK inhibition on
cellular metabolism was carried out by McDonnell et al.,
focusing on anaplastic large cell lymphoma (ALCL) cell
lines SU-DHL-1, DEL, Karpas299, SUPM2 and using ALK
inhibitor CEP-26939 (CEP, unknown mechanism of
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action, Cephalon) [58]. Metabolomic analysis by both
gas chromatography–mass spectrometry and liquid
chromatography-mass spectrometry displayed a signifi-
cant decrease in lactate following 3 h of treatment by
300 nM of CEP, which was accompanied by a decrease
in phosphorylated LDH detected by phosphoproteo-
mics via metal oxide affinity chromatography (MOAC)
[58]. Using 13C–glucose, they could demonstrate that
lactate in these cell lines was derived directly from glu-
cose, suggesting reduction of glycolytic flux following
ALK inhibition. Moreover, reduced glycolytic flux oc-
curred to be due to a decreased glucose uptake and re-
duced metabolites such as FBP, G6P and F6P [58]. In
addition, ribose-5-phosphate and xylulose-5-phosphate,
main metabolites in PPP, were significantly downregu-
lated following inhibition of ALK [58]. On contrary, no
similar metabolic changes were detected in ALK-
negative Jurkat cells treated by CEP, used as a negative
control [58]. Of clinical importance is the fact that
comparable results were observed also using crizotinib
[58]. Altogether, the data in this study provided a ra-
tionale that PKM2 is functioning as a mediator of ALK-
regulated metabolic switch as inhibition of ALK resulted
in reduction of pY105 PKM2, without a change in total
PKM2 levels [58].
Differently from what was reported previously using
other TKIs, Hudson and colleagues treated mouse
pancreatic ductal adenocarcinoma (PDAC) cell lines
from pancreatic cancer mouse model (KrasG12DPdx1-
cre) with axitinib (Inlyta®, mechanism of action
through VEGFR, c-KIT and PDGFR) and did not ob-
serve the expected effect on glycolysis and [C-14]
deoxyglucose uptake was increased in axitinib-treated
cells after 24 and 48 h [59]. It has to be considered,
however, that these experiments were performed with
axitinib-resistant PDAC clones, surviving after longer
incubation times or higher concentrations of axitinib
[59]. These results suggest that the increased glucose
uptake following axitinib treatment is involved in the
resistance mechanism towards the inhibitor-induced
anti-cancer effect. Moreover, the treatment with in-
creasing concentrations of axitinib upregulated
GLUT1 together with ECAR, proposing a way
through which axitinib induces glucose uptake [59].
Sorafenib (Nexavar®), a multikinase inhibitor targeting
BRAF, PDGFR and VEGFR, enhanced in the hepatocho-
langiocarcinoma cell line LCSC-2 the expression of
GLUT3, Enolase 2 (ENO2), and the platelet phospho-
fructokinase (PFKP), three genes directly associated with
glycolysis, hence suggesting a metabolic shift towards
glucose metabolism [60]. Indeed, the response to sorafe-
nib also induced uptake of the fluorescent glucose
analogue 6NDBG, glucose consumption and lactate pro-
duction [60]. The gene signature that emerges following
treatment with sorafenib indicates an induction of glyco-
lytic readjustment as a response to mitochondrial col-
lapse [60].
In another study, FGFR1 inhibition by TKI258/doviti-
nib, a multikinase inhibitor (VEGFR, FGFR, PDGF, c-
KIT, CSF-1R), significantly increased enzymatic activity
of PKM2 in human myeloid leukemia cell line KG1,
breast cancer cell line MDA-MB-134 and a lung cancer
cell line NCI-H1299, all three of them overexpressing
FGFR1 [61]. Additional data that suggest a role for
FGFR1 in modulating glucose energy metabolism were
provided recently by Fumarola et al. [62]. Using squa-
mous cell lung cancer (SQCLC) cell lines H1703 and
H520 after FGF2 induction, they could show that the
protein expression of both HIF-1α and GLUT1 corre-
lated with elevated glucose uptake, glycolysis, lactate
production and elevated PKM2 activity. Treatment with
a selective FGFR inhibitor NVP-BGJ398 or with a multi-
kinase inhibitor dovitinib hindered all these processes,
pointing towards AKT/mTOR pathway as a key player
in this regard. Importantly, the involvement of FGFR1
signaling affecting glucose metabolism was equally con-
firmed in vivo with LENTI-4 cells with FGFR1 amplifi-
cation generated from SQCLC SKMES-1 cells by
lentiviral expression [62].
TCA cycle and energy metabolism
TCA cycle is commonly presented in a simple viewpoint
of a cyclic mitochondrial pathway continually oxidizing
acetyl-CoA to CO2, spawning NADH and FADH2,
whose electrons are used in electron transport chain
(ETC) to generate ATP for chemical and physical work
within the cell [16]. Mitochondrial metabolism plays
a role in tumorigenesis [63] and furthermore, major
mitochondrial enzymes and pathways reinforce tumor
progression induced by key oncogenic drivers [64, 65].
Dominant defects associated with oncogenesis were re-
ported for succinate dehydrogenase (SDH), fumarate
hydratase (FH) and isocitrate dehydrogenase (IDH) [66].
These mutations in enzymes underlie the mechanistic
rationale on how alterations in the mitochondrial pathway
can potentially change bioenergetics of the cell itself. In this
chapter we discuss potent TKIs that were shown to perturb
pathways and metabolites included in mitochondria metab-
olism such as TCA components, ETC complexes and me-
tabolites related to oxidative phosphorylation (OXPHOS).
In the already mentioned study focusing on imatinib-
treated BCR-ABL-positive cells, the increase of mito-
chondrial glucose metabolism following treatment by
high imatinib concentration (above the IC50 value of
2.5 μmol/L) was accompanied by a higher energy state
(e.g., with an increase of all phosphate nucleoside tri-
phosphates (NTPs)), being possibly a result of an activa-
tion of the TCA cycle together with dysregulation of
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glucose metabolism [45]. The energy metabolism in
BCR-ABL-negative HC-1 cell line was not affected by
imatinib [45]. The TCA cycle metabolite α-ketoglutaric
acid was significantly reduced upon treatment with the
selective MET inhibitor capmatinib in two TNBC
mesenchymal-like cell lines MDA-MB-231 and Hs578.
Similarly, TCA cycle and central carbon metabolites
such as aspartate, fumarate and malate were decreased
following erlotinib treatment [30]. Impact on TCA cycle
was described in another study using LAD adenocarcin-
oma cell lines treated with either erlotinib or gefitinib
[27]. Despite the unchanged levels of acetyl-CoA follow-
ing the distribution of these TKIs, other metabolites
such as fumarate, malate and citrate were downregulated
in EGFRi-responsive HCC827 and PC-9 cells [27]. This
suggests that glutaminolysis is decreased after inhibition
of EGFR signaling, consistent with the lower expression
levels of glutaminase [27]. Moreover, although the inhi-
bition of EGFR signaling downregulated de novo py-
rimidine biosynthesis (reported downregulation of
phosphorylation of ribosomal protein S6 kinase 1 (S6K),
CAD trifunctional multi-domain protein (carbamoyl-
phosphate synthetase 2, aspartate transcarbamoylase and
dihydroorotase)), adenosine triphosphate levels (ATP)
were not affected [27]. It was proposed, that after the
treatment with WZ4002, an EGFR inhibitor, ATP levels
increased in H1975 cell line. The results were constant
with the results for H1993 cell line, exposed to another
MET inhibitor, PHA665752, suggesting a reactivation ef-
fort of mitochondrial respiration following the treatment
with the inhibitors [32]. To support this hypothesis, it
has been further shown that ALK inhibition induces up-
regulation in total ATP levels while downregulating ADP
in favour of biomass production (amino acids, lipids)
[58]. The evidence from these data points towards the
possibility that the reduction in glycolytic flux following
ALK inhibition is not a characteristic feature of a viable
cell since ATP levels are normally used as a representa-
tion of viability [67].
However, similarly to a previous study [27], an en-
hanced expression of ETC complexes II, III, IV and V
was observed using erlotinib for the treatment of EGFR-
sensitive HCC827 cells along with increased citrate
levels, while no alterations of malate values were de-
tected [32]. Comparable results indicating dysregulation
of mitochondria by a TKI were obtained by Guo et al.,
who reported a deregulation of eight mitochondrial pro-
teins (SLC25A13, NDUFS3, SDHB, UQCRC1, UQCRC2,
COX2, COX5A, CYC1) representative of all four com-
ponents of ETC and a decrease of mitochondrial perme-
ability transition pore (mPTP) in response to the MET
inhibitor PHA665752 in gastric carcinoma cell line
SNU5 [55]. In a more recent study, Tesori and col-
leagues described a dose-dependent increase of reactive
oxygen species (ROS), 12 h after exposure of the rat
hepatocholangiocarcinoma cell line LCSC-2 to sorafenib
[60]. Since mitochondria are a major source of ROS,
they indicated that the observed increase of ROS is
reflecting an impact of sorafenib on these energy sources
[60]. Indeed, sorafenib was shown to depolarize mito-
chondria, interfering with the mitochondrial function
and deregulating one of the mitochondrial enzymes,
pyruvate dehydrogenase alpha 1 (PDHA1), which cataly-
ses the production acetyl-CoA [60]. Furthermore, ATP
levels were reduced, proposing that LCSC-2 cells
strongly depend on mitochondrial functionality and that
this drug interacts directly with mitochondria [60]. In
addition, a 2017 study by Fumarola et al. using FGFR-
amplified cell line H1703 reported, that FGFR1 inhib-
ition by dovitinib or NVP-BGJ398 prevented ATP produc-
tion and that decreased ATP levels caused activation of
AMPK, a master energy sensor activated by elevated
AMP:ADP ratio within the cell [62]. Aforementioned evi-
dence uncovered novel mechanisms through which in-
hibitors act on mitochondrial biomarkers such as TCA
cycle, NTPs and acetyl-CoA. Although the reported re-
sults are not always consistent across distinct TK sys-
tems, most of these studies agree, that upon TKI
treatment cancer cells develop efforts to reactivate
mitochondria and functionality of mitochondrial respir-
ation as a potential saving mechanism against rapidly
lethal effects of targeted therapies.
Metabolism of amino acids and their products
High demand for protein synthesis in tumors boosts the
enormous need for amino acids. The mTOR pathway, a
signaling cascade mobilized by many different onco-
genes, is a one of the major pathways strongly associated
with amino acid metabolism [68]. Tumor cells have a
particular interest in amino acids such as serine and gly-
cine, which fuel synthesis of nucleotides, proteins and
lipids needed for proliferation [69, 70] and asparagine,
which regulates the uptake of amino acids, hence the in-
creased asparagine synthetase having role in a drug re-
sistance [71]. Interestingly, amino acid deregulation
plays an important function in immune tolerance in can-
cer [17]. Since T cells need for their proliferation trypto-
phan, amino acid depleted in many types of cancers,
their response to fight this neoplastic phenotype is lim-
ited [72]. Furthermore, some cancers are auxotrophic for
arginine, an amino acid playing role in urea, ornithine
and citrulline production [17, 73]. Considering the influ-
ence that amino acid metabolism has on the reprogram-
ming of neoplastic metabolism, we discuss in this
section known effects of TKIs on amino acids and their
related metabolites and appropriate enzymes.
In a study published in 2015, where the objective was
to comparatively profile the metabolite composition of
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hepatocellular carcinoma HepG2 cells treated solely
with sorafenib or everolimus (formerly RAD001, a
mTOR inhibitor), and the combination of these two
drugs using a NMR-based metabolomic approach, the
group of Ji-Xiang Zhang reported that key metabolites
are significantly altered in everolimus-treated cells
[74]. Aspartate and glutathione disulfide were not
changed in sorafenib-treated cells, however, alanine,
arginine and glycine were significantly decreased in
everolimus-treated cells. When comparing changes
occurring between sorafenib and combination treat-
ment, the combination therapy significantly downreg-
ulated molecules such as leucine, alanine, arginine
and glycine. Combination-treated cells encountered
decrease in arginine and increase in valine, lysine,
tyrosine and aspartate as compared to the changes in-
duced by the everolimus therapy, thus proposing that
sorafenib and everolimus may, in addition to their in-
dividually induced effects on the cells, act on the me-
tabolism of HepG2 cells also synergistically [74].
Further, it has been reported that amino acids proline
and aspartate were increased following erlotinib treat-
ment in EGFR-sensitive LAD cells [27]. Supporting
these findings, a study looking for potential RTK in-
hibition biomarkers for TNBC models reported that
in the basal-like cell line MDA-MB-231, perturbation
of amino acid metabolism (e.g., glycine, alanine, cyst-
ine, glycolic acid, valine, leucine, proline and trypto-
phan) occurs upon erlotinib or capmatinib treatment
[30]. Moreover, the authors of this study could fur-
ther demonstrate that suppression of tryptophan me-
tabolism enhances capmatinib treatment [30]. Other
recent work highlights significant changes in glycine,
serine and threonine metabolism in response to ALK
inhibition as a consequence of deregulation of PKM2
[58], which may regulate de novo serine synthesis via
3-phosphoglycerate [75].
Comparable to the aforementioned, metabolic profil-
ing of gefitinib-sensitive myeloma cancer cells LP-1 re-
vealed upregulation of threonine, histidine, proline,
asparagine and tyrosine following EGFR inhibition by
gefitinib [34]. Related to gefitinib treatment, it has
been reported that the concentration of arginine in
breast cancer patients is significantly reduced [76]. The
results of this study suggest that depletion of arginine
in malignancies, for which arginine is auxotrophic, can
be exploited as a potential targeted therapy [77]. At
this point it is important to clarify that arginine is a
nonessential amino acid in a healthy environment,
however it is essential for highly proliferating cells
[77]. In the aforementioned report by Gent et al., tryp-
tophan, a major determinant marker of metastasis
competence, did not change upon EGFR inhibition
with the small molecule inhibitor gefitinib, widening
the gap between the in vitro findings and their in vivo
translation [78].
To fulfil biosynthetic demands associated with prolif-
eration, tumors increase the import of nutrients includ-
ing amino acids for their survival. Studies discussed in
this section suggest that many amino acids are consist-
ently decreased following the treatment with TKs inhibi-
tors. Since most of these reports have been primarily
focused on changes in glucose and mitochondrial metab-
olism, we are only starting to unravel the extent to
which amino acids contribute to tumors’ pathology and
if fluctuations in their levels that occur upon administra-
tion of TKIs could be plausibly considered as markers of
therapy efficacy, or are rather merely passengers of
events that take place upon inhibition of the respective
oncogenic kinases.
Lipid metabolism
Although phospholipids, fatty acids and cholesterol rep-
resent extensive energetic storage and important build-
ing blocks for plasma membrane, impact on lipid
metabolism in cancer cells received less attention than
changes in glucose or amino acid metabolism. At the
same time it has been well established that cancerous
tissues are defined also by an increased rate of lipid syn-
thesis [79]. Transcription factor sterol regulatory
element-binding protein 1c (SREBP-1c) regulated by
mTORC1 promotes tumor progression by increasing de
novo lipid synthesis [80], which potentially implicates
mTORC2 in the control of lipogenesis. Although lipids
are extensively used as cancer biomarkers (e.g., phospho-
lipid levels for breast cancer [81] or apolipoprotein A-I
for colorectal cancer [82]), our current knowledge con-
cerning the impact of TKIs on lipid metabolites and
pathways is rather limited. The aforementioned study by
Gottschalk et al. reported a significant decrease of phos-
phocholine, a precursor for membrane synthesis, as a
consequence of the inhibition of cell proliferation in
imatinib-treated BCR-ABL-positive cells [45]. At the
same time, no changes were detected is BCR-ABL-
negative HC-1 cell line following imatinib treatment
[45]. It has been proposed that phosphocholine accumu-
lates in different types of tumors (for example in breast,
ovary or colon) as a result of an enhanced choline trans-
port into the cells [83–85] and the high increase of
phosphocholine is used as a marker for various cancers
with higher proliferation rate. Imatinib-induced drop in
phosphocholine reported by Gottschalk was accompanied
by an upregulation glycerophosphocholine [45], related to
apoptotic processes and membrane degradation [86]. In
this respect, a 2015 study by Zheng et al. revealed that low
dosage of sorafenib treatment affects glycerophospholipid
metabolism in hepatocellular carcinoma cells HepG2 [74].
Interestingly, the treatment with non-tyrosine kinase
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inhibitors, including inhibitors of PI3K and RAS, mostly
lead to downregulation of choline-containing metabolite
levels, composed of total choline, phosphocholine and gly-
cerophosphocholine [87–89]. In addition, a study con-
ducted by Lanning et al. reported perturbed lipid
metabolism which was present in more than 15% of total
hits in a metabolomics study assessing responses of TNBC
cancer cell lines to EGFR and MET inhibition. Interest-
ingly, MDA-MB-231 and Hs578T cell lines were sensitive
to the knockdown of fatty acid genes upon erlotinib treat-
ment whereas capmatinib (INC280) sensitized MDA-MB-
468 cells to knockdown of arachidonic and linoleic acid
metabolism rate limiting enzymes, providing an additional
motivation for co-targeting the metabolic and kinase path-
ways in TNBC patients [30].
Taken together, although our current expertise regard-
ing alterations in lipid metabolism upon distribution of
distinct TKIs is rather limited, the aforementioned re-
sults strongly suggest that TK inhibition often leads to a
decrease in levels of fatty acid metabolites such as phos-
phocholine. Given the central role that lipids are playing
in tumor development and tumor progression, further
investigations regarding potential clinical relevance of
TKI-related modulations in lipid metabolism are needed.
Conclusions
The introduction of TKIs to the armamentarium for the
modulation of growth factor signaling has revolutionized
treatment outcome of many cancer patients. Neverthe-
less, acquisition of drug resistance and reported side ef-
fects strongly limit their clinical use. Importantly,
molecular mechanisms responsible for these complex
processes induced by TKIs are not sufficiently under-
stood yet. Metabolomics, either as a unique approach or
in use in combination with other omics technologies, is
a highly effective approach not only for biomarker dis-
covery but has also the potential to unravel molecular
processes that underlie mechanisms of action of various
compounds including TKIs.
Nowadays it is relatively well established that TKIs
such as imatinib, erlotinib or gefitinib impose metabolic
changes on glycolysis profile of cancer cells expressing
their respective targets. Indeed, recent studies show that
these compounds decrease glucose uptake, potentially
affecting major players of glucose metabolism such as
transporters and rate limiting enyzmes, and by still un-
known mechanisms contribute to side effects such as re-
activation effort of mitochondrial respiration. On the
contrary, metabolic effects of TKIs on amino acid and
lipid metabolism are much less clear and cannot be gen-
eralized yet.
In summary, although the current knowledge on TKIs
impact on cellular metabolism is continuously expand-
ing, the detailed molecular mechanisms underlying
many of the observations described within this review
remain largely unknown and further biological investiga-
tions are warranted to understand the metabolic on- and
off-target effects related to TKIs treatment.
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